BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK 38.00
-0.90 (-2.31%)
Aug 1, 2025, 5:29 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 22.06M SEK in the quarter ending March 31, 2025, with 271.26% growth. This brings the company's revenue in the last twelve months to 60.80M, down -0.57% year-over-year. In the year 2024, BioInvent International AB had annual revenue of 44.69M, down -37.47%.
Revenue (ttm)
60.80M
Revenue Growth
-0.57%
P/S Ratio
41.13
Revenue / Employee
515.29K
Employees
114
Market Cap
2.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.97B |
| Sectra AB | 3.31B |
| Getinge AB | 35.50B |
| Camurus AB | 2.27B |
| Medicover AB | 25.22B |
| Asker Healthcare Group AB | 15.88B |
| Bonesupport Holding AB | 1.06B |
| AddLife AB | 10.44B |
BioInvent International AB News
- 11 months ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga